By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

Danish pharmaceutical behemoth Novo Nordisk reported better-than-expected net profit in the fourth quarter, amid soaring ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

Ozempic and Wegovy has been prescribed to Yorkshire patients hundreds of times in the past year - and it's not for weightloss ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on ...

A charity boss who once tipped the scales at more than 28st says weight-loss injections have changed the way he thinks about ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Wegovy sales increased by more than 100% over 2024. But that wasn’t enough to satiate analysts who want to know why Novo Nordisk can’t access more patients, particularly in the U.S.